Large-scale bioreactor expansion of tumor-infiltrating lymphocytes

Journal of Immunological Methods

Volumn 364, Issue 1-2, 2011, Pages 94-100

  Sadeghi, Arian ^a   Pauler, Linnea ^b   Annerén, Cecilia ^b,c   Friberg, Andrew ^a   Brandhorst, Daniel ^a   Korsgren, Olle ^a   Tötterman, Thomas H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GE Healthcare Bio Sciences AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Adoptive cell therapy; Bioreactor; Cell expansion; Melanoma; Static culture; Tumor infiltrating lymphocytes; WAVE bioreactor

Indexed keywords

INTERLEUKIN 2;

ARTICLE; BIOREACTOR; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CELL VIABILITY; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANTINEOPLASTIC PROTOCOLS; BIOREACTORS; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; SKIN NEOPLASMS;

EID: 78650849200     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.11.007     Document Type: Article

References (21)

1. Carlsson B., Cheng W.S., Totterman T.H., Essand M. Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp 65-modified dendritic cells as stimulators. Br. J. Haematol. 2003, 121:428.
2. Carlsson B., Sadeghi A., Bengtsson M., Wagenius G., Totterman T.H. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines. J. Immunother. 2008, 31:633.
3. Carswell K.S., Papoutsakis E.T. Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: shear, proliferation, and the IL-2 receptor. Biotechnol. Bioeng. 2000, 68:328.
4. Dudley M.E., Rosenberg S.A. Adoptive cell transfer therapy. Semin. Oncol. 2007, 34:524.
5. Dudley M.E., Wunderlich J.R., Shelton T.E., Even J., Rosenberg S.A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003, 26:332.
6. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346.
7. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233.
8. Foster A.E., Forrester K., Gottlieb D.J., Barton G.W., Romagnoli J.A., Bradstock K.F. Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture. Biotechnol. Bioeng. 2004, 85:138.
9. Garland R.J., Kaneria S.S., Hancock J.P., Steward C.G., Rowbottom A.W. The use of Teflon cell culture bags to expand functionally active CD8+ cytotoxic T lymphocytes. J. Immunol. Meth. 1999, 227:53.
10. Hami L.S., Green C., Leshinsky N., Markham E., Miller K., Craig S. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy 2004, 6:554.
11. Klapper J.A., Thomasian A.A., Smith D.M., Gorgas G.C., Wunderlich J.R., Smith F.O., Hampson B.S., Rosenberg S.A., Dudley M.E. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J. Immunol. Meth. 2009, 345:90.
12. Lamers C.H., Gratama J.W., Luider-Vrieling B., Bolhuis R.L., Bast E.J. Large-scale production of natural cytokines during activation and expansion of human T lymphocytes in hollow fiber bioreactor cultures. J. Immunother. 1999, 22:299.
13. Lamers C.H., van Elzakker P., Langeveld S.C., Sleijfer S., Gratama J.W. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy 2006, 8:542.
14. Levine B.L., Cotte J., Small C.C., Carroll R.G., Riley J.L., Bernstein W.B., Van Epps D.E., Hardwick R.A., June C.H. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J. Hematother. 1998, 7:437.
15. Malone C.C., Schiltz P.M., Mackintosh A.D., Beutel L.D., Heinemann F.S., Dillman R.O. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Cancer Biother. Radiopharm. 2001, 16:381.
16. Muul L.M., Spiess P.J., Director E.P., Rosenberg S.A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 1987, 138:989.
17. Newland M., Greenfield P.F., Reid S. Hybridoma growth limitations: the roles of energy metabolism and ammonia production. Cytotechnology 1990, 3:215.
18. Riddell S.R., Greenberg P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Meth. 1990, 128:189.
19. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 2009, 21:233.
20. Tran C.A., Burton L., Russom D., Wagner J.R., Jensen M.C., Forman S.J., DiGiusto D.L. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity. J. Immunother. 2007, 30:644.
21. Tran K.Q., Zhou J., Durflinger K.H., Langhan M.M., Shelton T.E., Wunderlich J.R., Robbins P.F., Rosenberg S.A., Dudley M.E. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 2008, 31:742.